Latest Financial Results


Revenue for the three and nine months ended September 30, 2021 was $1.2 million and $4.7 million, respectively, compared to $1.2 million and $2.5 million for the same periods in 2020.


As of September 30, 2021, Adaptimmune had cash and cash equivalents of $42.9 million and Total Liquidity1 of $240.1 million.

1Total liquidity is a non-GAAP financial measure, which is explained and reconciled to the most directly comparable financial measures prepared in accordance with GAAP below.

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2020

For complete information regarding our financials, see our periodic filings

Email Alerts

Stay informed and receive company updates straight to your inbox.

Sign up today
Developing Innovative Cancer Immunotherapy Products

Developing Innovative Cancer Immunotherapy Products

Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors.

Adaptimmune at a Glance


Responses in six solid tumor indications demonstrate SPEAR T-cell potential to treat cancer.


The Company aims to launch ADP‑A2M4 for sarcoma in 2022.


Following our June 2020 public offering, we raised approximately $243 million to advance the development of our therapies into and through clinical trials as well as for other general corporate purposes.

As of June 4, 2020


1H 2020

✔ Responses in solid tumors outside sarcoma

✔ Co-development and co-commercialization agreement with Astellas

✔ Data update from allogeneic program at scientific meeting

✔ Full presentation of ADP-A2M4 Phase 1 trial

  • Initiation of ADP-A2M4 with pembrolizumab. in combination trial in head & neck cancer

2H 2020

  • Safety update on Cohorts 1 & 2 of ADP-A2AFP Phase 1 trial*
  • Update on Cohort 3 of the ADP-A2AFP Phase 1 trial*
  • Updates on dose escalation cohorts from SURPASS trial*
  • Update on ADP-A2M4 Phase 1 radiation sub-study*
  • Update on ADP-A2AFP expansion cohort*
  • Additional durability and translational data from patients with synovial sarcoma from ADP-A2M4 Phase 1 trial*

2021 and beyond

  • Next products into clinic
  • Data from SPEARHEAD-1
  • ADP-A2M4CD8 Phase 2 trial in GEJ cancer
  • Phase 2 trials in additional indications
  • Allogeneic program update
  • ADP-A2M4 launch in sarcoma in the US in 2022

*at medical conferences

As of June 18, 2020 • June 2020 Corporate Deck

Collaborating with Industry Leaders

We partner with industry leaders from all areas of business on our proprietary T-cell therapies.

Alpine Immune Sciences

Alpine Immune Sciences





MD Anderson

MD Anderson



Universal Cells

Universal Cells

Our Pipeline

Adaptimmune’s affinity enhanced T-cell therapies work with the immune system to improve detection and targeting of cancer cells, resulting in the destruction of those cancer cells. We believe that the unique potential of immunotherapy will revolutionize the treatment of oncology in the future and that we are at the forefront of immunotherapy development

View Pipeline

T-cell Therapy Pipeline

We are tackling cancer with our affinity enhanced t-cell therapies. They work with the body’s immune system to improve the detection and targeting of cancer cells.

View Pipeline

Innovative Technology

Adaptimmune has an industry-leading technology platform which enables identification of targets, engineering and selection of T-cell receptors to targets and the preclinical screening of our end T-cell therapies.

View Technology

Ongoing Clinical Trials

We are conducting clinical trials with three SPEAR T-cells therapies (ADP-A2M4, ADP-A2AFP, and ADP-A2M4CD8) in ten solid tumors. The clinical trials are taking place at numerous sites in five countries.

View Clinical Trials

Resources for Patients & Families

Our team is focused on helping patients with cancer reach their goals. To assist with this, we provide resources on our clinical trials, T-cell therapies and cancer types.

View Resources

Investor Relations Contact Information

T: 215-825-9306

For other contact information, please visit the Contact page.